Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy

Next Previous
Search
Trial Profile

An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eteplirsen (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Registrational
  • Sponsors Sarepta Therapeutics

    • Most Recent Events

    • 01 Sep 2022 Results of post-hoc pooled analysis comparing percentage of predicted forced vital capacity and projected time with pulmonary function in patients with Duchenne muscular dystrophy from clinical studies 204 and 301 or standard of care (SoC; Cooperative International Neuromuscular Research Group Duchenne Natural History Study) published in the Muscle and Nerve
    • 01 May 2020 Results of an analysis from two clinical studies: study 204 (n=20) and study 301 (n=42) assessing temporal patterns of forced vital capacity in glucocorticoid-treated patients were presented at the 72nd Annual Meeting of the American Academy of Neurology
    • 10 May 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top